Icro Meattini, MD, University of Florence, Florence, Italy, highlights the significance of two late-breaking abstracts presented at the European Society of Radiation Oncology (ESTRO) annual meeting. Dr Meattini emphasizes that moderate hypofractionation in patients with high-risk non-metastatic breast cancer is not inferior to conventional fractionation in terms of lymphedema, and that a Phase III trial demonstrated the equivalence of moderate hypofractionation to standard care. Additionally, a 10-year update of the Phase III FAST-Forward trial (ISRCTN19906132) confirmed the equivalence of one-week whole-breast irradiation to moderately hypofractionated whole-breast irradiation in terms of local control, toxicity, safety, and survival outcomes, making these trials practice-changing for patient-centered care. This interview took place at the ESTRO 2025 congress in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
